cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30023039.v1
title: Has positional economic voting taken root in Eastern Europe?

description: In recent years scholars started exploring new dimensions of the economic vote: patrimony (asset ownership) and positional economic voting. Mushrooming literature in this field finds evidence that both of these dimensions make important contributions to the explanation of voters’ choices. This empirical confirmation may carry a strong “advance democracy bias.” Previous scholarly work has only scratched the surface of studying positional economic voting in other countries. We know little about positional economic voting in Eastern Europe (EE). Whether and to what extent this is happening, remains an open question that needs an empirical investigation. While we remain agnostic, at the outset of the study, we formulate a working hypothesis in favor of positional economic voting. By combining data from nine rounds of the European Social Survey (ESS) and five modules of Comparative Study of Electoral Systems (CSES), the study tests these propositions and seeks to identify which factors contribute to positional voting in the region. We found evidence that some positional voting is happening in EE. This occurs significantly more often for individuals who follow politics. Additionally, the rate of unemployment and fragmentation of the party system contribute to more positional voting in EE.
DOI: 10.6084/m9.figshare.29356555.v1
title: PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-Mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis

description: Immunotherapy combined with chemotherapy has emerged as a potential strategy to overcome tyrosine kinase inhibitors (TKIs)-resistant for advanced non-small-cell lung cancer (NSCLC); however, the efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy (PIC) compared to chemotherapy alone require further investigation. Phase III randomized controlled trials (RCTs) were systematically searched from 6 databases. Pooled hazard ratios (HRs) for survival outcomes and risk ratios (RRs) for responses and adverse events (AEs) were calculated. Three phase III RCTs were included in the final analysis. The PIC therapy significantly improved overall survival (OS) (HR: 0.86, 95% CI: 0.75-1.00, <i>p</i> = 0.04) and progression-free survival (PFS) (HR: 0.78, 95% CI: 0.68-0.90, <i>p</i> = 0.0005) compared to chemotherapy alone. While PIC therapy improved survival in the overall population, no significant benefit was observed for patients with brain metastases and non-sensitizing EGFR mutations. However, the incidence of immune-related AEs (irAEs) (RR: 2.02, 95% CI: 1.45-2.81, <i>p</i> &lt; 0.0001) and grade 3-5 irAEs (RR: 2.02, 95% CI: 1.03-3.98, <i>p</i> = 0.04) were increased. PIC therapy may provide a survival benefit for patients with TKIs-resistant, EGFR-mutant advanced NSCLC. Moreover, this potential benefit should be weighed against the increased risk of irAEs. PROSPERO (CRD42024615907).
DOI: 10.6084/m9.figshare.29356812
title: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data

description: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume mHSPC. Phase III randomized clinical trials of abiraterone were selected. Individual patient data (IPD) for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy. Survival analysis was performed using Cox hazards model. Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59–0.73) and PFS (HR: 0.51, 95% CI 0.45–0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1–2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3–4 events increased (RR 1.33). The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All <i>p</i> &lt; 0.05). Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation shouldvalidate these findings in real world setting. <b>PROSPERO:</b> (CRD420251028079).
DOI: 10.6084/m9.figshare.29356812.v1
title: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data

description: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume mHSPC. Phase III randomized clinical trials of abiraterone were selected. Individual patient data (IPD) for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy. Survival analysis was performed using Cox hazards model. Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59–0.73) and PFS (HR: 0.51, 95% CI 0.45–0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1–2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3–4 events increased (RR 1.33). The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All <i>p</i> &lt; 0.05). Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation shouldvalidate these findings in real world setting. <b>PROSPERO:</b> (CRD420251028079).
DOI: 10.6084/m9.figshare.29429970
title: Liver metastases in breast cancer: [<sup>18</sup>F]FDG and radioembolization as strategies for diagnosis and treatment

description: This review aims to analyze the role of [<sup>18</sup>F]FDG PET/CT and transarterial radioembolization (TARE) in managing liver metastases (LM) in breast cancer (BC), from metabolic characterization to treatment, to assess their impact on patient outcomes. A systematic search in PubMed and Embase (up to October 2024) identified studies on [<sup>18</sup>F]FDG PET imaging for LM in BC. Filters excluded reviews, case reports, and abstracts. Twenty-seven papers were selected, 19 were relative to the accuracy of [<sup>18</sup>F]FDG PET/CT and 8 to TARE. [<sup>18</sup>F]FDG PET/CT detected distant metastases in 10–100% of cases and LM in 0.3–38%. In most studies, PET/CT outperformed ceCT in detecting LM, though one study reported higher detection with ceCT (30.3% vs. 21.1%). The overall response rate to TARE was superior to 60%, while the overall survival ranged from 6.1 to 35.4 months, with minor severe adverse events. [<sup>18</sup>F]FDG PET/CT has a high accuracy in LM detection, and TARE has a high therapeutic potential in metastatic BC. Indeed, the optimization of imaging and personalized treatment strategies may enhance patient outcomes, also by considering the future perspectives.
DOI: 10.6084/m9.figshare.29429970.v2
title: Liver metastases in breast cancer: [<sup>18</sup>F]FDG and radioembolization as strategies for diagnosis and treatment

description: This review aims to analyze the role of [<sup>18</sup>F]FDG PET/CT and transarterial radioembolization (TARE) in managing liver metastases (LM) in breast cancer (BC), from metabolic characterization to treatment, to assess their impact on patient outcomes. A systematic search in PubMed and Embase (up to October 2024) identified studies on [<sup>18</sup>F]FDG PET imaging for LM in BC. Filters excluded reviews, case reports, and abstracts. Twenty-seven papers were selected, 19 were relative to the accuracy of [<sup>18</sup>F]FDG PET/CT and 8 to TARE. [<sup>18</sup>F]FDG PET/CT detected distant metastases in 10–100% of cases and LM in 0.3–38%. In most studies, PET/CT outperformed ceCT in detecting LM, though one study reported higher detection with ceCT (30.3% vs. 21.1%). The overall response rate to TARE was superior to 60%, while the overall survival ranged from 6.1 to 35.4 months, with minor severe adverse events. [<sup>18</sup>F]FDG PET/CT has a high accuracy in LM detection, and TARE has a high therapeutic potential in metastatic BC. Indeed, the optimization of imaging and personalized treatment strategies may enhance patient outcomes, also by considering the future perspectives.
DOI: 10.6084/m9.figshare.29429970.v1
title: Liver metastases in breast cancer: [18F]FDG and radioembolization as strategies for diagnosis and treatment

description: This review aims to analyze the role of [<sup>18</sup>F]FDG PET/CT and transarterial radioembolization (TARE) in managing liver metastases (LM) in breast cancer (BC), from metabolic characterization to treatment, to assess their impact on patient outcomes. A systematic search in PubMed and Embase (up to October 2024) identified studies on [<sup>18</sup>F]FDG PET imaging for LM in BC. Filters excluded reviews, case reports, and abstracts. Twenty-seven papers were selected, 19 were relative to the accuracy of [<sup>18</sup>F]FDG PET/CT and 8 to TARE. [<sup>18</sup>F]FDG PET/CT detected distant metastases in 10–100% of cases and LM in 0.3–38%. In most studies, PET/CT outperformed ceCT in detecting LM, though one study reported higher detection with ceCT (30.3% vs. 21.1%). The overall response rate to TARE was superior to 60%, while the overall survival ranged from 6.1 to 35.4 months, with minor severe adverse events. [<sup>18</sup>F]FDG PET/CT has a high accuracy in LM detection and TARE has a high therapeutic potential in metastatic BC. Indeed, the optimization of imaging and personalized treatment strategies may enhance patient outcomes, also by considering the future perspectives.
DOI: 10.6084/m9.figshare.29233690.v1
title: Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged ≥50 years

description: Lacking national policy for adult pneumococcal vaccination, local Indian guidelines recommend 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPV23). However, no vaccination (‘NV’) or PPV23 alone are most common in clinical practice. We evaluated cost-effectiveness of PCV13 versus NV and, alternatively, PPV23 in India. Cohort model with Markov-type process projected lifetime cases, deaths, and costs associated with invasive pneumococcal disease and all-cause non-bacteremic pneumonia (discounting = 5%/year). Cost per quality-adjusted life year (QALY) gained was assessed among at-risk/high-risk adults aged 50–59 years and all aged 60–99 years (<i>N</i> = 209.5 M) from private/patient and government/payer perspectives, which differed on medical costs, vaccination costs, and uptake rates. From private/patient perspective, PCV13 versus NV yielded ₹480,908/QALY (ΔCosts=₹27.2B;ΔQALYs = 56,560), whereas PCV13 was dominant versus PPV23 (ΔCosts=-₹359.1 M; ΔQALYs = 53,861).From government/payer perspective, corresponding ratios were ₹610,178/QALY (ΔCosts=₹84.4B;ΔQALYs = 138,382), and ₹456,048/QALY (ΔCosts=₹60.2B; ΔQALYs = 131,933). In probabilistic sensitivity analyses, cost-effectiveness was &lt;₹600,000/QALY in 72.9%-99.7% of replications (<i>N</i> = 1000/analysis), depending on comparison/perspective. PCV13 versus NV among at-risk/high-risk adults aged 50–59 years and all aged ≥ 60 years would be cost-effective from both perspectives considering willingness-to-pay equaling approximately 3× gross domestic product/capita. Furthermore, PCV13 versus PPV23 would be cost-effective and cost saving from government/payer and private/patient perspectives, respectively.
DOI: 10.6084/m9.figshare.29233690
title: Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged ≥50 years

description: Lacking national policy for adult pneumococcal vaccination, local Indian guidelines recommend 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPV23). However, no vaccination (‘NV’) or PPV23 alone are most common in clinical practice. We evaluated cost-effectiveness of PCV13 versus NV and, alternatively, PPV23 in India. Cohort model with Markov-type process projected lifetime cases, deaths, and costs associated with invasive pneumococcal disease and all-cause non-bacteremic pneumonia (discounting = 5%/year). Cost per quality-adjusted life year (QALY) gained was assessed among at-risk/high-risk adults aged 50–59 years and all aged 60–99 years (<i>N</i> = 209.5 M) from private/patient and government/payer perspectives, which differed on medical costs, vaccination costs, and uptake rates. From private/patient perspective, PCV13 versus NV yielded ₹480,908/QALY (ΔCosts=₹27.2B;ΔQALYs = 56,560), whereas PCV13 was dominant versus PPV23 (ΔCosts=-₹359.1 M; ΔQALYs = 53,861).From government/payer perspective, corresponding ratios were ₹610,178/QALY (ΔCosts=₹84.4B;ΔQALYs = 138,382), and ₹456,048/QALY (ΔCosts=₹60.2B; ΔQALYs = 131,933). In probabilistic sensitivity analyses, cost-effectiveness was &lt;₹600,000/QALY in 72.9%-99.7% of replications (<i>N</i> = 1000/analysis), depending on comparison/perspective. PCV13 versus NV among at-risk/high-risk adults aged 50–59 years and all aged ≥ 60 years would be cost-effective from both perspectives considering willingness-to-pay equaling approximately 3× gross domestic product/capita. Furthermore, PCV13 versus PPV23 would be cost-effective and cost saving from government/payer and private/patient perspectives, respectively.
DOI: 10.6084/m9.figshare.29505894
title: Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies

description: Tumor-agnostic treatments represent paradigm shift in oncology, targeting specific genetic mutations irrespective of the tumor’s anatomical origin. This personalized approach relies on companion diagnostic testing to identify patients likely to respond to treatment. However, incorporating molecular diagnostics poses challenges to healthcare systems, particularly regarding costs and accessibility. This must be addressed in economic evaluations to guide health technology assessment and reimbursement decisions. This study reviewed economic evaluations of tumor-agnostic therapies, focusing on the role of diagnostic testing. A literature search identified 13 compounds targeting nine molecular alterations, with eight relevant publications analyzed. The review revealed heterogeneity in how diagnostic testing is incorporated into cost-effectiveness models. While some studies excluded the costs and consequences of diagnostic tests entirely, others included them partially or fully. Key findings underscore the substantial impact of testing, particularly for low-prevalence biomarkers. Integrating diagnostic testing into economic evaluations is essential for accurately assessing the health economic value of tumor-agnostic therapies. Economic models must account for test-treatment combinations and consider shifts in treatment pathways compared to routine practice. As the field evolves, the development of robust frameworks and clear guidance on the requirements are crucial to support sustainable and equitable healthcare decision-making.
DOI: 10.6084/m9.figshare.29505894.v1
title: Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies

description: Tumor-agnostic treatments represent paradigm shift in oncology, targeting specific genetic mutations irrespective of the tumor’s anatomical origin. This personalized approach relies on companion diagnostic testing to identify patients likely to respond to treatment. However, incorporating molecular diagnostics poses challenges to healthcare systems, particularly regarding costs and accessibility. This must be addressed in economic evaluations to guide health technology assessment and reimbursement decisions. This study reviewed economic evaluations of tumor-agnostic therapies, focusing on the role of diagnostic testing. A literature search identified 13 compounds targeting nine molecular alterations, with eight relevant publications analyzed. The review revealed heterogeneity in how diagnostic testing is incorporated into cost-effectiveness models. While some studies excluded the costs and consequences of diagnostic tests entirely, others included them partially or fully. Key findings underscore the substantial impact of testing, particularly for low-prevalence biomarkers. Integrating diagnostic testing into economic evaluations is essential for accurately assessing the health economic value of tumor-agnostic therapies. Economic models must account for test-treatment combinations and consider shifts in treatment pathways compared to routine practice. As the field evolves, the development of robust frameworks and clear guidance on the requirements are crucial to support sustainable and equitable healthcare decision-making.
DOI: 10.6084/m9.figshare.29348661.v1
title: Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers

description: In most developed countries, overall survival rates for low-riskcancers (e.g. localized prostate and thyroid cancer) are comparable tothose of the general population. The general population’s survival rate mayserve as an upper bound for survival in people with these cancers. By applying this concept, we demonstrated limitations of using Markovmodels for low-risk cancers, and proposed an alternative modellingapproach.  Markov disease progression models typically depict a gradual progressionfrom early to advanced cancer stages and an increasing risk of cancer-specificmortality over time. However, data showed that the risk of death from cancer wasoften the greatest within the first few years following diagnosis. We thereforeproposed an alternative modeling approach. This method involves calculatingthe average quality-adjusted life-years (QALYs) from the integrals of thesurvival curve, multiplied by the corresponding health utility curve.Alternatively, QALYs may be estimated by averaging survival and utility withineach time interval and summing these estimates across intervals. We also appliedthese concepts to the critical appraisal of published economic evaluations. Understanding the upper bound of survival for low-risk cancers enableshealth economists to more accurately conduct cost-effectiveness analyses andassess the credibility of published economic evaluations.
DOI: 10.20348/storedb/1225/1344
title: Determination of the radon progeny activity size distribution at different types of workplaces
title: Structured summary of measurements conducted at selected workplaces in the Czech Republic.

description: Inhalation of radon and its short-lived progeny is one of the most significant contributors to the total effective dose from natural sources of ionising radiation. Exposure to radon progeny represents a substantial health risk, primarily due to its established link to lung cancer. Dose coefficients are derived from biokinetic models describing the behaviour of radon decay products in the respiratory tract, combined with dosimetric models that account for energy deposition from emitted radiation.
Given the variability of environmental and working conditions at different workplaces, obtaining site-specific aerosol data to support more accurate and tailored dose coefficient calculations is beneficial. The key parameters influencing effective dose include the equilibrium equivalent activity concentration (EEAC), total aerosol concentration, and the size distribution of radioactive aerosol particles. Additional factors such as work activity, relative humidity, and ventilation type significantly affect aerosol characteristics and, consequently, the equilibrium factor (F) and the unattached fraction (fp), which can vary considerably between sites.
This study presents field measurements of the activity size distribution of short-lived radon progeny at several workplaces, using the Dekati ELPI + cascade impactor and the Graded Screen Array Diffusion Battery (GSA DB). The measurements were conducted primarily at underground workplaces with natural ventilation, including former mining excavations and tourist caves. For comparison, the study also includes one site with forced ventilation—a facility for disposing of low-level radioactive waste—and one outdoor location influenced by radon exhalation from a uranium mining waste rock dump
description: Data file 1 presents a structured summary of measurements conducted at selected workplaces in the Czech Republic. The primary results include radon concentrations, equilibrium equivalent activity concentration (EEAC), and the determination of the unattached fraction. Additionally, the database provides information on workplace ventilation conditions, as well as the primary operational focus of each workplace. Data file 2 compiles structured records of personal dosimeters employed in Deliverable 5.10 – Report on in-situ intercomparison measurement campaign. For each dosimeter type, the database provides standardized information including model identification, country of origin, and the primary exposure pathway monitored. The dataset is intended to ensure traceability, comparability, and reproducibility of results obtained during the measurement campaign. More data are available on request.
DOI: 10.5281/zenodo.16880232
title: Project Jarāʾid: Snapshot of bibliographic metadata from Wikidata for all Arabic periodicals published worldwide before 1930

description: Monthly snapshot of all bibliographic data from Wikidata for Arabic periodicals published worldwide before 1930. This repository contains RDF for all Wikidata items of the first-order (i.e. periodicals), serialised in Turtle and JSON-LD.

The data set comprises titles, type of publication, publication dates, intervals, editors, places of publication and holdings.
DOI: 10.15468/dl.24xsms
title: Occurrence Download

description: A dataset containing 31 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Silene flammulifolia Steud. ex A.Rich."
 ]
}

 The dataset includes 31 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0109879-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ghfn9s
title: Occurrence Download

description: A dataset containing 3 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "TaxonKey is Phyllostachys bambusoides Siebold & Zucc.",
 "Year 2004-2024"
 ]
}

 The dataset includes 3 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0109880-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.484q25
title: Occurrence Download

description: A dataset containing 4 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Silene zhongbaensis (L.H.Zhou) C.Y.Wu, C.L.Tang & Flora Reipubl.Popularis Sin."
 ]
}

 The dataset includes 4 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0109881-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.